Neonatal Pulmonary Hemorrhage: Emergency Drug Management & Ventilation Protocol Guide

Neonatal Pulmonary Hemorrhage: A Life-Threatening NICU Emergency

Neonatal pulmonary hemorrhage is one of the most dramatic and acutely life-threatening emergencies in the NICU, characterized by the sudden appearance of blood or blood-tinged fluid from the endotracheal tube or airway. It occurs in approximately 1-12 per 1000 live births, with significantly higher rates in extremely low birth weight (ELBW) neonates. The mortality rate ranges from 30-50% when massive. Rapid intervention with airway management, ventilation optimization, pharmacological therapy, and correction of underlying coagulopathy is essential for survival. NNF India and international guidelines emphasize the need for a systematic emergency protocol at every NICU bedside.

Pathophysiology: Hemorrhagic Pulmonary Edema

Most cases of neonatal pulmonary hemorrhage are not due to rupture of large pulmonary vessels, but rather represent hemorrhagic pulmonary edema. The hematocrit of tracheal aspirate is typically 15-25%, much lower than venous blood. The primary mechanism involves increased pulmonary capillary pressure, most commonly from a hemodynamically significant patent ductus arteriosus (PDA), causing transudation of red blood cells and plasma into the alveolar space.

Risk Factors

Risk Factor	Mechanism	Relative Risk
Extreme prematurity (below 28 weeks)	Immature pulmonary vasculature, coagulopathy	High
Hemodynamically significant PDA	Pulmonary overcirculation and capillary leak	Very high
Post-surfactant therapy	Rapid compliance change increases PDA shunting	Moderate
Coagulopathy (DIC, thrombocytopenia)	Impaired hemostasis	High
Sepsis	Capillary leak, DIC, vasodilation	High
Birth asphyxia	Myocardial dysfunction, acidosis	Moderate
Hypothermia	Coagulopathy, poor cardiac function	Moderate
IUGR/SGA	Polycythemia, impaired clotting factors	Moderate

Emergency Management Algorithm

1. Secure airway: Intubate immediately if not already intubated; use an appropriately sized ETT
2. Suction ETT: Gentle suctioning to clear blood and maintain airway patency; avoid excessive deep suctioning which worsens hemorrhage
3. Increase PEEP: Raise to 6-8 cmH2O (up to 10 cmH2O if needed) to provide alveolar tamponade
4. Increase FiO2: To 1.0 initially; titrate based on SpO2
5. Intratracheal epinephrine: 0.1-0.3 mL/kg of 1:10,000 solution instilled via ETT for local vasoconstriction
6. Correct coagulopathy: Administer FFP 10-15 mL/kg, platelets if count below 50,000/mcL, cryoprecipitate if fibrinogen below 100 mg/dL
7. Packed RBC transfusion: 10-15 mL/kg if significant blood loss or hemoglobin drop
8. Surfactant: Consider 100-200 mg/kg once hemorrhage is partially controlled (blood inactivates surfactant)
9. Address PDA: If hemodynamically significant, initiate medical closure (ibuprofen or paracetamol)
10. Consider HFOV: If oxygenation remains poor on conventional ventilation with high PEEP

Pharmacological Interventions

Intratracheal Epinephrine

Parameter	Details
Concentration	1:10,000 (0.1 mg/mL)
Dose	0.1-0.3 mL/kg via ETT
Mechanism	Local pulmonary vasoconstriction reduces capillary leak and hemorrhage
Repeat	Can repeat every 5-10 minutes for 2-3 doses
Evidence level	Low (based on case series and clinical practice); widely used

Surfactant Replacement

Blood and plasma proteins in the alveolar space rapidly inactivate surfactant, creating a vicious cycle of atelectasis, worsened gas exchange, and further hemorrhage. Exogenous surfactant replacement can break this cycle:

• Poractant alfa: 100-200 mg/kg intratracheal
• Beractant: 100 mg/kg intratracheal
• Timing: After initial stabilization and partial hemorrhage control; not during active torrential bleeding
• Evidence: Several case series show improved oxygenation and survival when surfactant is given after pulmonary hemorrhage

Blood Product Management

Product	Dose	Indication	Target
Packed RBCs	10-15 mL/kg	Significant blood loss, Hb drop	Hb above 12 g/dL during active hemorrhage
Fresh Frozen Plasma	10-15 mL/kg	Coagulopathy, prolonged PT/APTT	Normalize PT/INR
Platelets	10-15 mL/kg	Count below 50,000/mcL	Above 100,000 during active bleeding
Cryoprecipitate	5-10 mL/kg	Fibrinogen below 100 mg/dL	Fibrinogen above 150 mg/dL

Ventilation Strategies During Pulmonary Hemorrhage

Ventilation management is crucial and must balance maintaining oxygenation with minimizing further lung injury:

Conventional Ventilation Settings

• PEEP: 6-8 cmH2O (increase to 10 if needed); the mechanical tamponade effect is the most important immediate ventilatory intervention
• PIP: Increase to maintain adequate tidal volumes (typically needs 20-25 cmH2O or higher)
• Rate: 40-60 breaths per minute
• Inspiratory time: 0.3-0.4 seconds
• FiO2: 1.0 initially, wean as tolerated

High-Frequency Oscillatory Ventilation (HFOV)

HFOV should be considered when conventional ventilation fails to maintain adequate oxygenation (OI above 20) or when air leak is a concern. Settings typically start with MAP 2-4 cmH2O above the failing conventional MAP, amplitude to achieve adequate chest wall vibration, and frequency of 10-15 Hz. HFOV provides superior mean airway pressure recruitment while minimizing barotrauma.

Addressing the Underlying Cause: PDA Management

Since hemodynamically significant PDA is the most common underlying cause, its management is integral to preventing recurrent hemorrhage:

Drug	Dose	Route	Course
Ibuprofen	10 mg/kg, then 5 mg/kg x 2	IV or PO	3 doses at 24-hour intervals
Paracetamol (Acetaminophen)	15 mg/kg	IV q6h or PO q6h	3-7 days
Indomethacin	0.1-0.2 mg/kg	IV	3 doses at 12-24 hour intervals

Monitoring and Reassessment

• Continuous SpO2, heart rate, and blood pressure monitoring
• Serial blood gas analysis every 1-2 hours during active hemorrhage
• Complete blood count with platelets every 4-6 hours
• Coagulation profile (PT, APTT, fibrinogen) at presentation and after blood product administration
• Echocardiography for PDA assessment and cardiac function
• Chest X-ray: typically shows bilateral diffuse opacification (white-out)
• ETT aspirate: monitor volume and color to track hemorrhage resolution

Prevention Strategies

Given the high mortality of pulmonary hemorrhage, prevention is critical:

• Antenatal corticosteroids to promote lung maturity and reduce PDA incidence
• Early targeted treatment of hemodynamically significant PDA
• Cautious surfactant administration with hemodynamic monitoring
• Maintaining normothermia (cold stress worsens coagulopathy)
• Vitamin K administration at birth (prevents hemorrhagic disease of the newborn)
• Conservative fluid management in ELBW neonates

Indian NICU Considerations

Pulmonary hemorrhage disproportionately affects preterm neonates in Indian NICUs where extreme prematurity survival rates are improving due to expanding Level III NICU capacity. HEAMAC neonatal care resources emphasize that every Indian NICU managing preterm neonates below 1500 g must have an emergency pulmonary hemorrhage protocol displayed at the bedside with pre-calculated doses of epinephrine, surfactant, and blood products. Access to blood bank products within 30 minutes is essential for units managing high-risk preterm neonates.

Conclusion

Neonatal pulmonary hemorrhage demands rapid, coordinated multisystem intervention. The combination of increased PEEP for mechanical tamponade, intratracheal epinephrine, correction of coagulopathy with blood products, surfactant replacement, and management of underlying PDA constitutes the comprehensive emergency approach. Indian NICUs at all levels should prepare for this emergency with standardized protocols, pre-calculated drug doses, and immediate access to blood products to improve survival in this devastating complication of prematurity.